Alzheimer's disease (AD) affects about 1 in 9 people above the age of 65 in the US, with projected healthcare costs reaching $1.1 trillion by 2050. Despite the severity of AD, there is no current cure, making it critical to improve current research and care. AD can be caused by a combination of genetic and environmental factors, complicating treatment efforts. However, CRISPR technology provides potential to treat the disease by manipulating certain genes involved in its pathogenesis. CRISPR treatments are currently being explored in mouse models of AD and human cells, and have the potential for improving therapeutics in human patients. The goal of this paper is to discuss how incorporating CRISPR into AD therapeutics can translate to improved care in humans.
No takes yet. Share an insight, caveat, or question.
Roya Bahman (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: